Assessment of the economic evaluation of the contrast agent Iomeron in percutaneous coronary intervention
Percutaneous coronary intervention (PCI - angiography and stent placement) aren't possible without X-ray contrast agents. Contrast enhancement depends on the iodine concentration, while the safety of particular contrast agents diff ers. Th e aim of the study is to conduct health economic evalua...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2018-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_cc6a39a2c60449ffaccd66e93c30742d | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a A. S. Kolbin |e author |
| 700 | 1 | 0 | |a I. A. Vilum |e author |
| 245 | 0 | 0 | |a Assessment of the economic evaluation of the contrast agent Iomeron in percutaneous coronary intervention |
| 260 | |b Izdatelstvo OKI, |c 2018-06-01T00:00:00Z. | ||
| 500 | |a 2588-0519 | ||
| 500 | |a 2618-8473 | ||
| 520 | |a Percutaneous coronary intervention (PCI - angiography and stent placement) aren't possible without X-ray contrast agents. Contrast enhancement depends on the iodine concentration, while the safety of particular contrast agents diff ers. Th e aim of the study is to conduct health economic evaluation of Iomeron (Bracco Imaging S.p.A., Italy) in patients with acute coronary artery disease treating with PCI. Th e cost-eff ectiveness analysis, cost-minimization analysis, sensitivity analysis and budget impact analysis were used. In results, we can say that Iomeron is cost-eff ective comparing to iodixanol, iohexol, iopromide and ioversol. | ||
| 546 | |a RU | ||
| 690 | |a чрескожное коронарное вмешательство | ||
| 690 | |a контрастный препарат | ||
| 690 | |a оценка медицинских технологий | ||
| 690 | |a анализ эффективности затрат | ||
| 690 | |a анализ минимизации затрат | ||
| 690 | |a анализ влияния на бюджет | ||
| 690 | |a Medical technology | ||
| 690 | |a R855-855.5 | ||
| 690 | |a Pharmacy and materia medica | ||
| 690 | |a RS1-441 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Качественная клиническая практика, Vol 0, Iss 1, Pp 68-76 (2018) | |
| 787 | 0 | |n https://www.clinvest.ru/jour/article/view/197 | |
| 787 | 0 | |n https://doaj.org/toc/2588-0519 | |
| 787 | 0 | |n https://doaj.org/toc/2618-8473 | |
| 856 | 4 | 1 | |u https://doaj.org/article/cc6a39a2c60449ffaccd66e93c30742d |z Connect to this object online. |